Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
Department of Medical Research and Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou Str, Goudi, 115 25, Athens, Greece.
Arch Osteoporos. 2020 Oct 16;15(1):163. doi: 10.1007/s11657-020-00837-x.
Use of the FRAX (Fracture Risk Assessment Tool) tool to assess fracture risk is the most common practice worldwide. Our findings suggest that in treatment-naïve women with osteopenia treatment would be cost-effective for approximately one-third of the study population and nearly half of the subjects over 75 years, according to the Greek-specific FRAX-based thresholds.
When evaluating a patient with low bone mineral density (BMD), fracture risk estimation is of paramount importance. Fracture risk assessment using the FRAX tool is the most common and most studied practice worldwide.
PATIENTS-METHODS: The primary aim of the "ACROSS" study was to record the 10-year probability of major osteoporotic fractures and hip fractures, using the Greek version of the FRAX tool, in a rather representative population of 230 postmenopausal treatment-naïve women with osteopenia. Secondary aims of the study were to identify (1) the risk for fractures according to age and the years from menopause, (2) the proportion of patients qualifying for treatment according to the Greek cost-effective FRAX thresholds, and (3) the perception of both the patient and the treating physician regarding the estimated fracture risk.
The mean 10-year risk was 10.7% ± 6.6 for major osteoporotic fractures and 3.4% ± 4.2 for hip fractures. For women up to 75 years of age, the 10-year risk for major osteoporotic and hip fractures was 8.8% and 2.1%, respectively, while for women over 75 years, the risk was 15.2% and 6.6%, respectively. Patients generally believed that they had low fracture risk independently of age, while the physicians considered that the risk increases with advancing age.
According to the Greek-specific FRAX-based thresholds, the administration of osteoporosis treatment would be cost-effective for approximately one-third of the study population and nearly half of the subjects over 75 years. Patients are not fully aware of their fracture risk.
使用 FRAX(骨折风险评估工具)评估骨折风险是全球最常见的做法。我们的研究结果表明,根据希腊特有的基于 FRAX 的阈值,在未经治疗的骨质疏松症女性中,约有三分之一的研究人群和近一半 75 岁以上的患者接受治疗具有成本效益。
在评估低骨密度(BMD)患者时,骨折风险评估至关重要。使用 FRAX 工具评估骨折风险是全球最常见和研究最多的方法。
患者-方法:“ACROSS”研究的主要目的是使用希腊版 FRAX 工具记录 230 名绝经后未经治疗的骨质疏松症女性的 10 年主要骨质疏松性骨折和髋部骨折的概率。该研究的次要目的是确定(1)根据年龄和绝经后年限的骨折风险,(2)根据希腊成本效益 FRAX 阈值符合治疗条件的患者比例,以及(3)患者和治疗医生对估计骨折风险的看法。
主要骨质疏松性骨折和髋部骨折的 10 年平均风险分别为 10.7%±6.6%和 3.4%±4.2%。对于 75 岁以下的女性,10 年主要骨质疏松性骨折和髋部骨折的风险分别为 8.8%和 2.1%,而对于 75 岁以上的女性,风险分别为 15.2%和 6.6%。患者普遍认为他们的骨折风险较低,而不论年龄大小,而医生认为风险随着年龄的增长而增加。
根据希腊特有的基于 FRAX 的阈值,骨质疏松症治疗的实施在研究人群中约有三分之一和近一半 75 岁以上的患者具有成本效益。患者并未充分意识到自己的骨折风险。